We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





PHASE Scientific Launches RNA Extraction Kit for COVID-19 Test

By LabMedica International staff writers
Posted on 10 Apr 2020
Print article
Image: PHASIFY VIRAL RNA Extraction Kit (Photo courtesy of PHASE Scientific)
Image: PHASIFY VIRAL RNA Extraction Kit (Photo courtesy of PHASE Scientific)
PHASE Scientific (Hong Kong) has commercially launched the PHASIFY VIRAL RNA Extraction Kit as part of its global effort to help detect and control the COVID-19 disease. PHASIFY VIRAL purifies and concentrates viral RNA in patient viral transport media samples. This novel technology outperforms conventional solid phase extraction methods in RNA yield and concentration.

PHASE Scientific is a biotech company which builds tools that empower people by giving them better information about their health. The PHASIFY VIRAL kit, which incorporates the PHASIFY proprietary liquid phase extraction technology, produces greater viral RNA yields. This is enabled by an increased sample input volume up to 1 mL per extraction, and enhanced final viral RNA concentration with flexible elution volume down to 10 µL. The kit’s easy-to-use design requires no additional specialized equipment, such as magnetic racks and vacuum pumps, for operation.

PHASIFY concentrates target molecules by 10-100x, making them easier to detect. PHASIFY can make any diagnostic test more affordable, faster, easier, and more accurate. As proven by validation data, the PHASIFY VIRAL RNA extraction kit enables a 3-6 cycle threshold reduction compared to solid phase extraction. The applications of the PHASIFY VIRAL RNA Extraction Kit can be expanded to cover a wide scope of RNA-type virus extractions to help research institutes, hospitals, and diagnostic labs to improve diagnostic performance.

“We believe the PHASIFY VIRAL kit will be a new breakthrough approach for the fight against the COVID-19 disease. Our products can help increase detection sensitivity, decrease false negative results, enable earlier detection and increase confidence in diagnostic test results,” said Ricky Chiu, Ph.D., Founder and CEO of PHASE Scientific.

Related Links:
PHASE Scientific

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 RT-PCR Assay
Reliance SARS-CoV-2 RT-PCR Assay Kit

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The QIAstat-Dx Analyzer 2.0 with remote test results access enhances collaboration across the healthcare system (Photo courtesy of QIAGEN)

Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access

QIAGEN (Venlo, the Netherlands) has released the QIAstat-Dx Analyzer 2.0, including the Software 1.6 upgrade. This represents a significant advancement from the initial QIAstat-Dx Analyzer 1.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The RedDrop One blood collection device has received 510(k) clearance from the U.S. FDA for prescription use (Photo courtesy of RedDrop Dx)

Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy

The discomfort associated with traditional blood draws leads to a significant issue: approximately 30% of diagnostic tests prescribed by physicians are never completed by patients. This avoidance is often... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.